Michael Wyzga - X4 Pharmaceuticals Chairman of the Board
| XFOR Stock | USD 1.09 0.08 6.84% |
Chairman
Michael Wyzga is Chairman of the Board of X4 Pharmaceuticals since 2019.
| Age | 63 |
| Tenure | 5 years |
| Address | 61 North Beacon Street, Boston, MA, United States, 02134 |
| Phone | 857 529 8300 |
| Web | https://www.x4pharma.com |
Michael Wyzga Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Wyzga against X4 Pharmaceuticals stock is an integral part of due diligence when investing in X4 Pharmaceuticals. Michael Wyzga insider activity provides valuable insight into whether X4 Pharmaceuticals is net buyers or sellers over its current business cycle. Note, X4 Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell X4 Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Wyzga over six months ago Purchase by Michael Wyzga of 25000 shares of X4 Pharmaceuticals | ||
Michael Wyzga over six months ago Acquisition by Michael Wyzga of 45000 shares of X4 Pharmaceuticals subject to Rule 16b-3 |
X4 Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4438) % which means that it has lost $0.4438 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6167) %, meaning that it created substantial loss on money invested by shareholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/30/2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -0.91. At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 04/30/2024, Net Tangible Assets is likely to grow to about 68.5 M, while Non Current Assets Total are likely to drop slightly above 19.2 M.Similar Executives
| Found 4 records | CHAIRMAN Age | ||
| Gary Jacob | Hepion Pharmaceuticals | 70 | |
| Douglas Treco | Inozyme PharmaInc | 66 | |
| Yves Sabbagh | Inozyme PharmaInc | N/A | |
| Peter Fellner | Mereo BioPharma Group | 73 | |
Management Performance
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.44 |
X4 Pharmaceuticals Leadership Team
Elected by the shareholders, the X4 Pharmaceuticals' board of directors comprises two types of representatives: X4 Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XFOR. The board's role is to monitor X4 Pharmaceuticals' management team and ensure that shareholders' interests are well served. X4 Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, X4 Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paula Ragan, President CEO, Secretary, Director | ||
| Rene Russo, Director | ||
| Michael Wyzga, Chairman of the Board | ||
| Adam Mostafa, CFO, Treasurer, Assistant Secretary | ||
| Renato Skerlj, Founder | ||
| Arthur Taveras, Chief Officer | ||
| Murray Stewart, Director | ||
| Murray MD, Interim Director | ||
| Mark MBA, Chief Officer | ||
| Stephanie Carrington, IR Contact Officer | ||
| Richard MD, Founder | ||
| MBA MD, Chief Officer | ||
| Robert Arbeit, Senior Research | ||
| Mary DiBiase, Chief Officer | ||
| Gary Bridger, Director | ||
| David Mantus, Chief Development Officer | ||
| Isaac Blech, Director | ||
| Keith MD, Founder Board | ||
| Pharm MPH, Vice Communications | ||
| Eszter Nagy, Co-Founder, Chief Scientific Officer, Managing Director of Arsanis Biosciences GmbH | ||
| David McGirr, Independent Director |
XFOR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is X4 Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 139.71 M | ||||
| Shares Outstanding | 167.94 M | ||||
| Shares Owned By Insiders | 0.83 % | ||||
| Shares Owned By Institutions | 61.31 % | ||||
| Number Of Shares Shorted | 12.26 M | ||||
| Price To Book | 4.39 X | ||||
| Price To Sales | 53.87 X | ||||
| Gross Profit | 3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether X4 Pharmaceuticals is a strong investment it is important to analyze X4 Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact X4 Pharmaceuticals' future performance. For an informed investment choice regarding XFOR Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for XFOR Stock analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (0.44) | Return On Equity (1.62) |
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.